Latest American Society of Clinical Oncology Stories
INDIANAPOLIS, May 14, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from more than 25 studies at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1 - 5, 2012, including overall survival results from PARAMOUNT, a Phase III study of an ALIMTA® (pemetrexed for injection)-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer. Lilly presented...
SUNNYVALE, Calif., May 10, 2012 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results and recent developments for its fiscal third quarter ended March 31, 2012. Financial Results for Third Quarter Ended March 31, 2012 The non-GAAP (Generally Accepted Accounting Principles) net loss reported for the fiscal quarter ended March 31, 2012 was $9.3 million, or $0.14 loss per share. This compares with a non-GAAP net loss of $7.4 million, or $0.12 loss per...
--Childhood Cancer Expert at The Children's Hospital of Philadelphia To Be Honored at ASCO Annual Meeting-- PHILADELPHIA, May 8, 2012 /PRNewswire-USNewswire/ -- Yael P. Mosse, M.D., who cares for patients with cancer at The Children's Hospital of Philadelphia, will receive the inaugural James B. Nachman ASCO Junior Faculty Award in Pediatric Oncology. The American Society of Clinical Oncology will honor Dr. Mosse with this special merit award during its annual meeting, occurring June...
WORCESTER, Mass. and TORONTO, May 8, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that abstracts featuring the AE37 breast cancer vaccine clinical program of Generex wholly-owned subsidiary Antigen Express, Inc. will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (http://chicago2012.asco.org) taking place June 1-5, 2012 in Chicago, IL. An abstract entitled "From bench to bedside: The use of the li-Key...
SAN DIEGO, April 3, 2012 /PRNewswire/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today that data from a Phase I clinical trial of the Company's lead drug candidate ME-143 has been selected for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 1-5, 2012, in Chicago. An abstract of the presentation, entitled "ME-143, a novel...
St. Jude Children's Research Hospital physician is the recipient of the 2012 Pediatric Oncology Award MEMPHIS, Tenn., March 20, 2012 /PRNewswire-USNewswire/ -- Ching-Hon Pui, M.D., a renowned leader in the research and treatment of childhood leukemia, is the recipient of the 2012 Pediatric Oncology Award from the American Society of Clinical Oncology (ASCO). The honor recognizes Pui's many contributions to better understanding the blood cancer's biology and treatment as well as his...
WILMINGTON, Del., Feb. 27, 2012 /PRNewswire-USNewswire/ -- Christiana Care Health System medical oncologist Stephen S. Grubbs, M.D., has been elected to a three-year term on the board of directors of the American Society of Clinical Oncology (ASCO), the world's leading professional organization representing physicians who care for people with cancer. (Photo: http://photos.prnewswire.com/prnh/20120227/DC59569) (Logo: http://photos.prnewswire.com/prnh/20090407/DC95299LOGO) Dr....
In this News Digest: Summary of the first prospective study – published online February 13, 2012 in the Journal of Clinical Oncology – to provide strong evidence of increased breast and pancreatic cancer risk in individuals with Lynch syndrome, who carry certain inherited genetic mutations in DNA repair genes. The study is also the first to show that relatives of people with Lynch syndrome who do not carry these mutations have no increased risk of cancer. Quote for...
HOBOKEN, N.J. and PHILADELPHIA, Feb. 1, 2012 /PRNewswire/ -- Niiki Pharma Inc. announced today the formation of its Scientific Advisory Board. Daniel Haller M.D. will chair the advisory board, and will be joined by Lee Ellis M.D. and Matt Kulke M.D. The Board will provide clinical and strategic guidance to the company for its two first-in-class clinical stage anti-cancer compounds, NKP-1339 and NKP-2235. As the pipeline continues to mature, the Advisory Board will be expanded....
BOTHELL, Wash. and VANCOUVER, British Columbia, Jan. 19, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that preliminary data from two studies evaluating their investigational compound OGX-427, in prostate and bladder cancer, will be presented at the American Society of Clinical Oncology (ASCO) 2012 Genitourinary Cancers Symposium, February 2-4, in San Francisco. OGX-427 is a novel compound designed to reduce levels of Heat Shock Protein 27...
